相关实验视频
Updated: Mar 22, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
96.1K
阿斯素,一个禁食诱导的葡萄糖蛋白激素
Chase Romere1, Clemens Duerrschmid1, Juan Bournat1
1Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Cell
|April 19, 2016
概括
研究人员发现阿斯素是一种禁食诱导的蛋白质激素, 降低阿斯普罗辛水平可显著降低胰岛素耐药个体的葡萄糖和胰岛素,提供潜在的II型糖尿病治疗方法.
科学领域:
- 代谢调节
- 内分泌学
- 分子生物学
背景情况:
- 肝脏释放的葡萄糖对于维持血糖平衡至关重要,尤其是在禁食期间.
- 激素调节精确地控制血葡萄糖水平.
- 特定的禁食激素在肝糖调节中的作用需要进一步阐明.
研究的目的:
- 识别和描述调节肝脏葡萄糖释放的新型禁食激素.
- 调查发现的激素的作用机制.
- 评估这种激素在代谢障碍中的治疗潜力.
主要方法:
- 鉴定了一种新型蛋白质激素 (阿斯素) 来自布利林裂变.
- 在人类和小鼠中测量循环阿斯素水平.
- 对阿斯素在肝脏中的信号通路 (G蛋白-cAMP-PKA) 的研究.
- 评估Asprosin在免疫或遗传切除后对葡萄糖和胰岛素水平的影响.
主要成果:
- 阿斯普罗辛是白色脂肪组织分泌的C端裂解产物.
- 在肝脏中激活G蛋白-cAMP-PKA通路,刺激葡萄糖的释放.
- 在抗胰岛素的人类和小鼠中观察到病理上升的阿斯普罗辛水平.
- 由于肝脏释放葡萄糖的减少,Asprosin功能丧失导致显著的葡萄糖和胰岛素减少.
结论:
- 阿斯素是一种新型的葡萄糖蛋白激素,在肝脏释放葡萄糖中起着关键作用.
- 治疗阿斯普罗辛可能是治疗II型糖尿病和代谢综合征的有希望的策略.
相关概念视频
Metabolic States of the Body: Fasting and Starvation
3.3K
During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
3.3K
Metabolic States of the Body: The Postabsorptive State
1.6K
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
1.6K
Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Hormones Regulating Blood Glucose
8.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
8.3K
Glucose Homeostasis: Regulation of Blood Glucose
5.1K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
5.1K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K

